Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 279109, 12 pages
http://dx.doi.org/10.1155/2015/279109
Research Article

Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy

1Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, China
2Department of Clinical Laboratory, Shengjing Hospital of China Medical University, Heping Ward, Shenyang, Liaoning 110003, China
3Department of Clinical Laboratory, The First Hospital of China Medical University, Heping Ward, Shenyang, Liaoning 110001, China
4Institute of Pathology and Pathophysiology, The First Hospital and College of Basic Medical Sciences of China Medical University, Heping Ward, Shenyang, Liaoning 110001, China

Received 8 June 2015; Revised 13 September 2015; Accepted 12 October 2015

Academic Editor: Siddharth Pratap

Copyright © 2015 Huizhe Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The genetic variants of the ATP-binding cassette, subfamily G, member 2 (ABCG2) are known to be involved in developing cancer risk and interindividual differences in chemotherapeutic response. The polymorphisms in ABCG2 gene were genotyped by using PCR-RFLP assays. We found that ABCG2 G34A GA/AA genotype, C421A AA genotype, and haplotypes 34A-421C and 34G-421A were significantly associated with increased risk for developing breast carcinoma. Furthermore, ABCG2 C421A AA homozygote had a significant enhanced therapeutic response in patients with neoadjuvant anthracycline-based chemotherapy. Moreover, ABCG2 G34A AA genotype carriers displayed a longer OS in ER positive patients or PR positive patients after postoperative anthracycline-based chemotherapy. These results suggested that the ABCG2 polymorphisms might be a candidate pharmacogenomic factor to assess susceptibility and prognosis for breast carcinoma patients.